AllCells

AllCells is excited to offer a 30% discount on Cryopreserved T Cells until October 8th. For inquiries or to place an immediate order, contact us: https://www.allcells.com/contact-us/

T cells are a key cell population involved in many cell and gene therapy programs given their potent immune effector and modulatory functions. Our latest blog features T cells and highlights some of the latest research findings. To view the blog post, please click here: https://web.allcells.com/tcells

Learn more about Good Manufacturing Practice guidelines and quality systems that can ensure the consistency and quality of the starting cellular material used for the development and commercialization of cellular therapies on our latest blog post. Click here: http://web.allcells.com/GMPblog

Natural killer (NK) cells are versatile immune effectors capable of antitumor activities that have piqued the interest of many scientists investigating cancer immunotherapies. Our latest blog highlights this unique cell type and the current strategies being utilized to enhance their specificity to increase their effectiveness against various forms of cancer. Click on the link to read more about NK cells: https://web.allcells.com/NKCells

This year's American Association for Cancer Research (AACR) virtual meeting will cover the latest discoveries across the spectrum of cancer researchfrom population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy. We’d love the opportunity to discuss how AllCells can help further your cancer research! Click on the to book a meeting with us during AACR: http://web.allcells.com/AACR2021

Welcoming. Progressive. Autonomous. These three words came to mind when Susie Wong, Production Lab Lead at AllCells, was asked to describe the company. As the Production Lab Lead, Susie is responsible for ensuring the smooth operation and organization of the production lab and its team members. We asked Susie... What do you like most about your job? What I like most about my job is learning new things. Since we are doing more custom projects, we are able to learn a variety ...of different techniques and invest in more aspects of product development. What is one piece of advice you have for others in your profession? Be confident, don’t doubt yourself, and go for it. If you are sure there is an opportunity, you need to believe wholeheartedly in ityour team won’t be driven to succeed unless you are.Kellee Khalil, Founder of Loverly Come join Susie and be part of the future of AllCells. Visit our careers page: https://www.allcells.com/about-allcells/careers/

Engineering T cells for use in immunotherapy strategies like CAR-T continue to advance at a rapid pace. This article provides a great summary of the latest CAR-T developments across the globe: https://www.biopharma-reporter.com//Scientific-breakthroug

Are you attending Advanced Therapies Connect 2020 next week? Let's connect! Book a meeting to chat with the AllCells Team: https://web.allcells.com/33ViF7b

AllCells is proud to announce the addition of Cryopreserved Leukopaks to our extensive product portfolio. Now, get the quality of fresh cells with the convenience of cryopreserved cells. Our state-of-the-art cryopreservation method enables consistently high post-thaw recovery and viability, and preserves the integrity of your order of high-quality primary cells. With protocols to boost efficiency and streamline workflow, AllCells is proud to offer a cryopreserved cell product with viability and quality that mirrors fresh cell products. Learn more about the key advantages of this groundbreaking product: https://web.allcells.com/2H4QOd1

AllCells announces expanded product portfolio: Guaranteed Cell-count Leukopaks! Our Guaranteed Cell-count Leukopaks are filled to deliver no less than 10 Billion, 5 Billion, or 2.5 Billion cells at release. Click here to learn more: https://www.allcells.com/tissue-products/leukopaks/

Mobilized peripheral blood (mobilized Leukopak, mLP) has become one of the most accessible and popular sources of CD34+ HSPCs for research and clinical use. To obtain HSPCs from mLP, donors are treated with mobilizing agents - Mozobil, Neupogen, or a combination of the two. This procedure results in large-scale yields of single-donor CD34+ HSPCs, allowing for scalability and reproducibility of experiments by limiting the impact of donor-to-donor variability. In this blog, our team of experts breaks down each mobilization regimen. Based on standardized ISHAGE protocol, all three mobilization regimens result in a significant increase in CD34+ cells in peripheral blood compared to normal, unmobilized blood, only 0.01 to 0.05%. https://web.allcells.com/2XKmWrB

AllCells is looking for a Customer Success Manager to join our growing team! https://web.allcells.com/2DSZdiw

AllCells announces expanded product portfolio: Guaranteed Cell-count Leukopaks! Our Guaranteed Cell-count Leukopaks are filled to deliver no less than 10 Billion, 5 Billion, or 2.5 Billion cells at release. Click here to learn more: https://www.allcells.com/tissue-products/leukopaks/

Mobilized peripheral blood (mobilized Leukopak, mLP) has become one of the most accessible and popular sources of CD34+ HSPCs for research and clinical use. To obtain HSPCs from mLP, donors are treated with mobilizing agents - Mozobil, Neupogen, or a combination of the two. This procedure results in large-scale yields of single-donor CD34+ HSPCs, allowing for scalability and reproducibility of experiments by limiting the impact of donor-to-donor variability. In this blog, our team of experts breaks down each mobilization regimen. Based on standardized ISHAGE protocol, all three mobilization regimens result in a significant increase in CD34+ cells in peripheral blood compared to normal, unmobilized blood, only 0.01 to 0.05%. https://web.allcells.com/2XKmWrB

AllCells is proud to be a partner for this year's Onco Cell Therapy Virtual Summit. Our team and designated territory representatives are excited to learn how AllCells can support you in your biomedical research. https://web.allcells.com/31VuNWy #OCTS #celltherapy #cancertherapy #immunology

East Coast Researchers! We're excited to announce that Armel Nibasumba has joined the AllCells team as a Business Development Regional Manager (East Coast) to support the demand out of our Quincy Massachusetts Donor Collection Facility. Armel offers a breadth of experience in #lifesciences and specializes in serving academia, biotechnology, and pharmaceutical companies. Once a researcher himself, Armel is well-acquainted with the need for Healthy Human, High Quality #PrimaryCells and is committed to providing on-time, flexible, high quality solutions. Welcome to AllCells, Armel! Connect with Armel: https://web.allcells.com/38d3Crc